Biolyst › INBSINTELLIGENT BIO SOLUTIONS INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.
The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There are 9 upcoming events on record.
Cash runway is approximately 4.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 43 concluded trials, 79% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
November 12, 2026 est.
Next quarterly earnings (projected) Earnings
—
November 30, 2026
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors Trial Milestone
Phase 1/Phase 2
December 31, 2026
Evaluate the Safety, Tolerability of BAT6026 Trial Milestone
Phase 1/Phase 2
February 28, 2027
A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants Trial Milestone
Phase 1
April 30, 2027
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema Trial Milestone
Phase 3
May 31, 2027
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection Trial Milestone
Phase 1
December 31, 2027
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders Trial Milestone
Phase 2
February 29, 2028
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors Trial Milestone
Phase 1/Phase 2
October 26, 2030
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis Trial Milestone
Phase 2/Phase 3
Track INBS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open INBS in the tracker
Recent history
Date Event Type Phase
October 13, 2026
8-K filed: Reg FD disclosure Filing
—
September 15, 2026
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Trial Milestone
Phase 2/Phase 3
September 11, 2026
8-K filed: Other event Filing
—
September 9, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
September 2, 2026
8-K filed: Material agreement, Reg FD disclosure Corporate
—
September 1, 2026
8-K filed: Reg FD disclosure Filing
—
August 28, 2026
8-K filed: Reg FD disclosure Filing
—
August 19, 2026
Quarterly results filed (8-K) Earnings
—
August 11, 2026
8-K filed: Reg FD disclosure Filing
—
August 5, 2026
8-K filed: Reg FD disclosure Filing
—
August 3, 2026
8-K filed: Other event Filing
—
August 3, 2026
8-K filed: Reg FD disclosure Filing
—
July 23, 2026
8-K filed: Reg FD disclosure Filing
—
July 21, 2026
8-K filed: Reg FD disclosure Filing
—
June 16, 2026
8-K filed: Reg FD disclosure Filing
—
June 2, 2026
8-K filed: Reg FD disclosure Filing
—
May 14, 2026
Quarterly results filed (8-K) Earnings
—
April 20, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
March 23, 2026
8-K filed: Leadership change, Other event Corporate
—
February 25, 2026
8-K filed: Reg FD disclosure Filing
—
February 12, 2026
Quarterly results filed (8-K) Earnings
—
February 5, 2026
Quarterly results filed (8-K) Earnings
—
January 28, 2026
8-K filed: Reg FD disclosure Filing
—
January 8, 2026
8-K filed: Other event Filing
—
January 2, 2026
8-K filed: Material agreement, Other event Corporate
—
December 31, 2025
8-K filed: Reg FD disclosure Filing
—
December 16, 2025
8-K filed: Listing / standard notice Corporate
—
December 12, 2025
8-K filed: Other event Filing
—
December 8, 2025
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection Trial Milestone
Phase 1
December 2, 2025
8-K filed: Reg FD disclosure Filing
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.